Date: Thursday, May 10, 2012
Time: 7:30 pm - 9:00 pm
Location: Hilton New Orleans Riverside, New Orleans, Louisiana
Room: Jefferson Ballroom

TARGET AUDIENCE
This activity has been designed to meet the educational needs of hematologists/oncologists, specialists in bleeding disorders, hemophilia treatment center clinicians, registered nurses, and other healthcare providers interested in managing congenital bleeding disorders and attending the 2012 American Society of Pediatric Hematology/Oncology (ASPHO) meeting, as well as registrants of the Blood CME Center.

STATEMENT OF NEED/PROGRAM OVERVIEW
Rare bleeding disorders (RBDs), coagulation deficiencies of factors I, II, V, V+VIII, VII, X, XI, and XIII, represent 3% to 5% of all inherited coagulation deficiencies worldwide and have a prevalence of approximately 1:500,000 to 1:1-3 million in the general population. Considered orphan diseases due to their rarity and neglected status, RBDs can present challenges to treating clinicians because their natural history and disease manifestations are not well established. Limited data and a lack of standardized treatment guidelines for RBDs make it difficult to determine prevalence, appropriate laboratory evaluations, and treatment strategies. In some instances, factor replacement therapy, the mainstay of treatment, is limited or not available at all in the United States, posing an additional challenge for clinicians as well as affected patients. However, knowledge of RBDs has increased within the past decade due to the advent of registries and databases that have begun the task of data collection and dissemination on a worldwide basis. This learning activity affords healthcare clinicians the opportunity to learn the latest information about RBDs, including symptom recognition, diagnostic workups, and treatment strategies, from bleeding disorders experts who work closely with national and international registries.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Present the bleeding phenotype, including clinical manifestations, for each of the rare bleeding disorders (RBDs) reviewed
• Describe the appropriate laboratory evaluation for a suspected RBD based on evidence and clinical utility of the diagnostic sensitivity/specificity of available coagulation assays
• Compare dosing and administration of available coagulation factor replacement therapy and hemostatic agents for these rare disorders
• Discuss national and international registries and databases and their importance to better understand the disease prevalence, diagnosis, and genotype/phenotype characterization of RBDs
• Review case studies and integrate expert recommendations into patient management strategies
• Provide appropriate care and counsel for patients and their families

CHAIRPERSON
Co-Chairpersons
Suchitra S. Acharya, MD
Program Head, Bleeding Disorders and Thrombosis Program
Cohen Children’s Medical Center of New York
Associate Professor of Pediatrics
Hofstra North Shore—LIJ School of Medicine
New Hyde Park, New York

Amy D. Shapiro, MD
Adjunct Professor of Pediatrics
Michigan State University
Medical Director
Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana

DISTINGUISHED FACULTY
Manuel Carcao, MD, FRCPC, MSc
Associate Professor
Co-Director, Hemophilia Clinic
Hospital for Sick Children
University of Toronto, Canada

Marilyn J. Manco-Johnson, MD
Professor of Pediatrics
University of Colorado School of Medicine
Director, Hemophilia & Thrombosis Center
Aurora, Colorado

Guglielmo Mariani, MD
Department of Internal Medicine and Public Health
University of L’Aquila Medical School
L’Aquila, Italy

Flora Peyvandi, MD
Associate Professor of Internal Medicine
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
IRCCS Maggiore Hospital
University of Milan
Milan, Italy


PROGRAM AGENDA

7:30 pm - 7:50 pm	Dinner & Introduction and Overview of Congenital Bleeding Disorders Amy D. Shapiro, MD/Suchitra S. Acharya, MD
7:50 pm - 8:20 pm	Clinical Presentation, Diagnosis, and Current and Emerging Treatment Options for Fibrinogen Disorders and FXIII Deficiency Marilyn J. Manco-Johnson, MD/Manuel Carcao, MD
8:20 pm - 8:35 pm	FVII Deficiency: Lessons Learned From the International FVII Registry and Seven Treatment Evaluation Registry (STER) Guglielmo Mariani, MD
8:35 pm - 8:50 pm	Optimizing Care for Rare Bleeding Disorders Through Harmonization of National and International Databases Flora Peyvandi, MD
8:50 pm - 9:00 pm	Q&A/Closing Remarks

PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION
Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

FEE INFORMATION
There is no registration fee for attending this symposium; however, seating is limited.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 3 weeks (if applicable).

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Client Services prior to the live event at (888) 588-1407.